News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Oncothyreon Inc. (ONTY)'s Lung Cancer Drug EMR 63325-009 Misses Primary Endpoint In Phase 1 Study



8/20/2014 6:12:35 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Merck KGaA (NYSE: MRK), Darmstadt, Germany, has informed Oncothyreon Inc. (Nasdaq: ONTY) that a randomized Phase 1/2 study, EMR 63325-009, of tecemotide compared to placebo in Japanese patients with Stage III non-small cell lung cancer did not meet its primary endpoint of an improvement in overall survival, and no treatment effect was seen in any of the secondary endpoints (progression free survival, time to progression or time to failure). A preliminary analysis of adverse events has not identified a clinically meaningful difference between study groups. The study was not powered to show statistical significance between the two arms. The study enrolled 178 patients in Japan, of which 94% had received concurrent chemoradiotherapy.

Hey, check out all the research scientist jobs. Post your resume today!

Read at Street Insider
Read at News Release


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES